Acute Bacterial Skin And Skin Structure Infections Industry Forecast to Hit $18.7 Billion by 2029 With a Strong 9.7% CAGR

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Acute Bacterial Skin And Skin Structure Infections Market Covering 2025–2034?

The acute bacterial skin and skin structure infections market has experienced substantial growth in recent years. It is forecast to increase from $11.75 billion in 2024 to $12.9 billion in 2025, achieving a compound annual growth rate (CAGR) of 9.7%. The expansion observed in past periods can be attributed to advancements in the healthcare industry, economic factors, shifts in patient demographics, developing diagnostic methodologies, and innovation in clinical trials.

The acute bacterial skin and skin structure infections market size is projected to experience substantial growth in the upcoming years. It will grow to “$18.7 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. This expansion during the forecast period is fueled by global epidemiological factors, the introduction of new therapies to the market, advanced rapid diagnostic tools, a patient-focused approach, and evolving treatment guidelines. Significant trends for the forecast period include patient population demographics, concerns regarding antibiotic resistance, progress in treatment strategies, the prevalence of methicillin-resistant staphylococcus aureus (mrsa), and an emphasis on outpatient treatment.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13282&type=smp

Which Drivers Are Impacting The Acute Bacterial Skin And Skin Structure Infections Market?

The increasing occurrence of skin infections is anticipated to boost the expansion of the acute bacterial skin and skin structure infections market in the future. Skin infections are medical conditions where microorganisms like bacteria, fungi, or viruses invade and proliferate within the skin, causing various signs and discomfort. This increase in skin infections generates a stronger need for therapeutic interventions, antibiotics, and advanced treatments to tackle acute bacterial and skin structure infections, ensuring optimal patient care and results. As an illustration, in March 2023, data from the World Health Organization, a specialized agency of the United Nations located in Switzerland, indicated that roughly 1.8 billion people worldwide experience skin conditions at any given moment. Neglected tropical diseases (NTDs) constitute approximately 10% of these cases, with fungal infections accounting for 34% and bacterial infections for 23%, frequently resulting in elevated mortality rates. Consequently, the growing prevalence of skin infections will propel the growth of the acute bacterial skin and skin structure infections market.

What Are The Leading Segments Analyzed In The Acute Bacterial Skin And Skin Structure Infections Market?

The acute bacterial skin and skin structure infectionsmarket covered in this report is segmented –

1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections; Community-Acquired Acute Bacterial Skin And Skin Structure Infections

2) By Active Ingredients: Delafloxacin; Vancomycin; Ceftaroline Fosamil; Oritavancin; Tedizolid; Daptomycin; Tigecycline; Linezolid; Other Active Ingredients

3) By Route Of Administration: Oral; Parenteral; Topical

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

5) By Application: Cellulitis; Abscess; Surgical Wounds; Traumatic Wound

Subsegments:

1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections; Catheter-Related Infections; Pressure Ulcers; Infections Related To Medical Devices

2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis; Abscesses; Impetigo; Folliculitis; Wound Infections

Which Trends Are Impacting The Acute Bacterial Skin And Skin Structure Infections Market?

Major companies operating in the acute bacterial skin and skin structure infections market are concentrating on developing novel single-dose therapies, exemplified by Dalbonova, to gain a competitive advantage. Dalbonova represents a single-dose treatment that delivers both convenience and effectiveness, enabling patients to achieve desired results with just one powerful 1500 mg dose administered on a single occasion. As an example, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that specializes in API (active pharmaceutical ingredient) and formulation therapeutic segments, including acute bacterial skin and skin structure infections, launched Dalbonova injection, a single-dose solution for acute bacterial skin and skin structure infections (ABSSSI). By offering a single-dose regimen and removing the requirement for hospital admissions, Dalbonova Injection significantly reduces the potential for hospital-acquired diseases. This medication is specifically designed to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain gram-positive microorganisms in patients across all age brackets, including newborns.

Which Key Players Are Driving Competition In The Acute Bacterial Skin And Skin Structure Infections Market?

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/acute-bacterial-skin-and-skin-structure-infections-global-market-report

What Are The Regional Market Dynamics Impacting The Acute Bacterial Skin And Skin Structure Infections Industry?

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Acute Bacterial Skin And Skin Structure Infections Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13282&type=smp

Browse Through More Reports Similar to the Global Acute Bacterial Skin And Skin Structure Infections Market 2025, By The Business Research Company

Antibacterial Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/antibacterial-products-global-market-report

Bacterial And Plasmid Vector Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bacterial-and-plasmid-vector-global-market-report

Dna Based Skin Care Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dna-based-skin-care-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info